StemCell Therapy

The 65 rating InvestorsObserver gives to BioNTech SE - ADR (BNTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, BNTXs 65 overall rating means the stock scores better than 65 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

BioNTech SE - ADR (BNTX) stock is up 2.67% while the S&P 500 is lower by -0.18% as of 10:49 AM on Tuesday, Dec 8. BNTX is higher by $3.35 from the previous closing price of $125.70 on volume of 2,210,886 shares. Over the past year the S&P 500 has gained 17.52% while BNTX is higher by 345.03%. BNTX lost -$1.01 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioNTech SE - ADR (BNTX) Stock.

Read the original:
Is BioNTech SE - ADR (BNTX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

BioXcel Therapeutics Inc (BTAI) is near the top in its industry group according to InvestorsObserver. BTAI gets an overall rating of 63. That means it scores higher than 63 percent of stocks. BioXcel Therapeutics Inc gets a 79 rank in the Biotechnology industry. Biotechnology is number 36 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

BioXcel Therapeutics Inc (BTAI) stock is up 3.5% while the S&P 500 is down -0.39% as of 2:26 PM on Monday, Dec 7. BTAI is higher by $1.60 from the previous closing price of $45.70 on volume of 185,902 shares. Over the past year the S&P 500 is higher by 17.49% while BTAI is higher by 667.86%. BTAI lost -$3.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.

See the original post:
Should You Buy BioXcel Therapeutics Inc (BTAI) in Biotechnology Industry? - InvestorsObserver

A grant from the federal Department of Education will improve resources in the school's Center for Biotechnology and also reach out to students in grades K-12.

FORT VALLEY, Ga. A new grant could help bring in more biotechnology students to Fort Valley State University.

Dr. Sarwan Dhir is the director for the Center of Biotechnology. He says for the next three years, the program at Fort Valley State University will have a new grant.

"In the last 20 years, biotechnology has changed the whole world," says Dhir.

"Right now, an example is that pharmaceutical and biotech companies are working together to solve the problem of COVID-19," he says.

Dhir says the grant is for almost $750,000, and it comes from the U.S. Department of Education.

He says it will not only help with tuition costs for current Wildcats, but also work to raise interest in biotechnology for elementary, middle, and high school aged kids.

"The grant is basically going to recruit 15 students and keep them for three years, but on top of that, we have another grant from the national science foundation that is actually going to provide them with the scholarship for $17,000 for four years," says Dhir.

There are currently 45 students in the program, and one of them is senior Tori McGuire, who says she's ready to start a Master's program next.

"I appreciate the money that he has set up and the money that he brings into here because I really haven't had this chance to have opportunities like this," she says about Dhir.

Freshman Dakota Walker says she came into the university as a marketing major, but soon changed majors after meeting Dhir. She says for students considering majoring in biotechnology, Fort Valley State is the only option.

"Plain and simple, because we're the best. There is no denying that. We're 100 percent the best, we have the resources, we have the faculty, we have a staff that wants to help you, we want to see you succeed," she says.

Dhir says to start, all programs and workshops will be virtual.

Continue reading here:
'Biotechnology has changed the world': Fort Valley State University receives grant to attract biotech majors - 13WMAZ.com

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax (WWV), a non-profit organization dedicated to building vaccine confidence, workforce security and countering vaccine misinformation, announced that executives from both organizations recently made public comments discussing the science of COVID-19 vaccines and the challenges of vaccine hesitancy and distribution.

Sia Anagnostou, Senior Director of Corporate Development for ITI and WWV Board Secretary, recently made public comments during the ACIP emergency meeting in support of the CDCs recommendation to allocate the initial COVID vaccine doses expected late Dec 2020 - Jan 2021 to health care workers and people living in long-term care facilities. In addition to the ACIP discussion, Dr. William Hearl, CEO of ITI and Chairman of WWV, was interviewed on Fox News 29 in Philadelphia to amplify the commentary on these topics.

It is important that leaders in the biotechnology community speak out wherever possible to effectively communicate the value, safety and efficacy of vaccines for COVID-19 and other infectious diseases, said Dr. Hearl. Participation in immunization education and support of Public Health efforts is of the utmost importance as we face the global challenge of this pandemic.

The public comments at ACIP and on Fox News are available here:

https://www.fox29.com/video/876822.amp

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, neoantigens and producing antigen-derived antibodies as biologics. In early 2020, an investment of over $60M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. The Company has built a large pipeline from UNITE with eight oncology programs, multiple animal health programs and a SARS-CoV-2 program to prevent and treat COVID-19. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.

About Why We Vaccinate, Inc.

WhyWeVax - http://www.whywevax.org - is a 501(3)(c) educational organization dedicated to provide a credible and trusted source for honest and factual information on vaccines, their efficacy, safety and importance to public health. WhyWeVax works to counter the misinformation, anti-science rhetoric and virulent fake news dissemination that question the safety and efficacy of vaccines for preventable infectious diseases. The development of a safe and effective vaccine for COVID-19 and its ultimate manufacture and distribution through the healthcare system will require a concerted effort by the biotechnology, academic, medical and scientific communities to meet the challenge of vaccine hesitancy and refusal. WhyWeVax will support educate the population to the value of vaccines to protect the health and safety of their families, their friends, their communities and our way of life.

See the original post here:
Immunomic Therapeutics Executives and Board Members of WhyWeVax Discuss COVID-19 Vaccine Issues with Fox News and CDC's ACIP Committee - Business Wire

Galectin Therapeutics Inc. Common Stock (GALT) is near the top in its industry group according to InvestorsObserver. GALT gets an overall rating of 60. That means it scores higher than 60 percent of stocks. Galectin Therapeutics Inc. Common Stock gets a 75 rank in the Biotechnology industry. Biotechnology is number 34 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Galectin Therapeutics Inc. Common Stock (GALT) stock is trading at $2.67 as of 10:41 AM on Tuesday, Dec 8, a loss of -$0.08, or -2.91% from the previous closing price of $2.75. The stock has traded between $2.62 and $2.71 so far today. Volume today is light. So far 75,489 shares have traded compared to average volume of 172,918 shares.

Click Here to get the full Stock Score Report on Galectin Therapeutics Inc. Common Stock (GALT) Stock.

Here is the original post:
Is Galectin Therapeutics Inc. Common Stock (GALT) The Right Choice in Biotechnology? - InvestorsObserver

The Narendra Modi-led Central government has announced that the second campus of the Rajiv Gandhi Centre for Biotechnology (RGCBT) in Thiruvananthapuram, Kerala, a premier molecular biology and biotechnology research centre now under the Ministry of Science and Technology, will be named after M.S. Golwalkar, the Rashtriya Swayamsewak Sangh (RSS) ideologue.

The announcement, made by Union Minister for Science and Technology Dr Harsh Vardhan on December 4 during his online address to the pre-inaugural session of the sixth edition of the International Science Festival, has taken Kerala by surprise.

The RGCBT had earlier announced that its second campus would be named the Centre for Complex Diseases in Cancer and Viral Infections.

Harsh Vardhans statement that the new campus is to be named "Shri Guruji Madhav Sadashiv Golwalkar National Centre for Complex Diseases in Cancer and Viral Infections", apparently as decided by the RGCBT governing body, has come without notice to or prior consultation with the State government, which originally established the RGCBT as a research & development centre. The State had subsequently handed over the centre to the Government of India for developing it as a centre of international standards in research and development.

Protests are mounting by the day in the State on the propriety of choosing to name the campus after a person whose abiding role has not been in science but in providing Hindutva forces an ideological base and an organisational structure to achieve a Hindu Rashtra.

The Bharatiya Janata Party (BJP) political leadership has come up with rather strange arguments to justify the move: (a) Golwalkar has an M.Sc. in Zoology and he left his studies while doing a Ph.D. in Marine Biology to become an active member of the RSS; (b) that he had a great vision about the scientific development of the country and his teachings and ideas are relevant in the present time; (c) the Left has given the names of several communist leaders jailed in 1947 and 1962 for anti-national activities to several institutions; (d) the Communist Party of India (Marxist) should explain the basis for naming a football stadium in Kozhikode after E.M.S. Namboodiripad; and (e) why is the renowned annual Nehru Trophy Boat Race in Kerala named after Jawaharlal Nehru? (the last question was raised as a justification by V. Muraleedharan, the Union Minister of State for External Affairs and Parliamentary Affairs).

The ruling and opposition parties in Kerala find themselves united as an offshoot of the controversy. Almost all political parties except the BJP have condemned the announcement to name the new campus after the RSS ideologue.

While Chief Minister Pinarayi Vijayan, in a letter to Union Minister Harsh Vardhan, suggested that the new campus should be named after some eminent Indian scientist of international repute, Opposition Leader Ramesh Chennithala said in a letter to Prime Minister Narendra Modi that the new campus should continue to function under the name of former Prime Minister Rajiv Gandhi.

Sashi Tharoor, MP from Thiruvananthapuram, said in a series of tweets on Twitter: What is MSGs [M.S. Golwalkar] contribution to science other than promoting the disease of communalism?; I suggest a local hero: Dr. P. Palpu, renowned bacteriologist and social reformer, born in Thiruvananthapuram in the year 1863. Expert in serum therapy and tropical medicine from Cambridge, Director of the Vaccine Institute and Fellow of the Royal Institute of Public Health. This forward-looking scientist and medical practitioner would be far more appropriate than an obscurantist ideologue of no scientific achievement and no discernible contribution to public health. Its a BJP insult to Thiruvananthapuram and should be resisted.

The Modi governments move cannot be seen in isolation, coming as it does after similar controversies over pleas for rewriting history from an Indian standpoint, the unveiling of the V.D. Sarvarkar portrait at the Central Hall of Parliament and the eulogisation in school textbooks and through the naming or renaming of airports, railway stations, bridges, streets and flyovers after Hindutvas other heroes such as K.B. Hedgewar and Deen Dayal Upadhyaya.

Moreover, if statements by V. Muraleedharan and other BJP leaders are any indication, the name Shri Guruji Madhav Sadashiv Golwalkar National Centre for Complex Diseases in Cancer and Viral Infections has been presented as a fait accompli and, significantly, as a strong political message in Left Front-ruled Kerala where the BJP has so far been unable to make much gains. It is also significant that the RGCBTs prestigious new campus also is in Thiruvananthapuram, where the BJP is hoping to make some significant gains in the ongoing local body elections and in the Assembly elections that is to follow soon.

For more on Golwalkar, read: What is Hindu Rashtra?

Read more:
Protests erupt in Kerala over the Central governments decision to name the second campus of the Rajiv Gandhi Centre for Biotechnology in...

New Jersey, United States,-

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: An analysis for future growth

Global Nanoparticles in Biotechnology and Pharmaceuticals Market report has added committed areas covering the tendencies of the target crowd and the opposition as of now present on the lookout. Because of the COVID-19 pandemic, numerous organizations have confronted a colossal plunge in their functions and sales. However, the Global Nanoparticles in Biotechnology and Pharmaceuticals market has pushed through this unpleasant market fix and came out with brilliant outcomes. This has pulled in the consideration of large organizations as well as the new companies too, to attempt their hands in one of the steadiest markets.

To comprehend the market elements and mainstays of the Global Nanoparticles in Biotechnology and Pharmaceuticals market, the report helps in unwinding the insider facts behind the consistent development of the market since initiation. Factors, for example, political situation, segments focal points and tendency of target crowd are a portion of the main considerations that either drive the business forward or pull them down.

Request Sample Copy of this Report @ Nanoparticles in Biotechnology and Pharmaceuticals Market Size

In market segmentation by manufacturers, the report covers the following companies-

Why is it important to understand the post-COVID19 Global Nanoparticles in Biotechnology and Pharmaceuticals -market?

The capital inflow and outpouring of the Global Nanoparticles in Biotechnology and Pharmaceuticals -market is consistent in any event, during the progressing pandemic, pushing it as one of the most solid organizations during the ongoing occasions. To measure the market openings, customers can exploit the recommendable activities pointed in the report. These activities are attempted and tried prior to imparting to customers to set aside their time and cash.

How to overcome obstacles for the septennial 2020-2027 using the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Presently, going to the main part-outside elements. Porters five powers are the main components to be thought of while moving into new business markets. The customers get the opportunity to use the approaches to plan the field-tested strategies without any preparation for the impending monetary years.

We have faith in our services and the data we share with our esteemed customers. In this way, we have done long periods of examination and top to bottom investigation of the Globalmarket to give out profound bits of knowledge about the Global Nanoparticles in Biotechnology and Pharmaceuticals market. Along these lines, the customers are enabled with the instruments of data (as far as raw numbers are concerned).

The graphs, diagrams and infographics are utilized to speak out about the market drifts that have formed the market. Past patterns uncover the market turbulences and the final results on the markets. Then again, the investigation of latest things uncovered the ways, the organizations must take for shaping themselves to line up with the market.

What type of data is added into the Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

Working corresponding to the market can be troublesome however not with the direction from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report shares the data gathered from the official sites of the administering bodies and the yearly reports of the current market players. Making the report reliable and trustworthy. Thusly, the market can be perceived from its foundations.

To accomplish greatest ROI alongside increasing most extreme lump of the market, the customers can use the information from the Global Nanoparticles in Biotechnology and Pharmaceuticals market report. The report gives step-wise strategies to accomplish for transient objectives. For understanding the drawn out objectives, the report grandstands the advantages of dealing with the partners and the encompassing individuals on the lookout. This will help the business endeavours in coming out with brilliant numbers.

What are the advantages of using Global Nanoparticles in Biotechnology and Pharmaceuticals market report?

The opponents referenced in the report are added for instance purposes and can be changed according to the prerequisites set forward by the customers. Advantages related with Global Nanoparticles in Biotechnology and Pharmaceuticals market report are recorded underneath:

1. Long-term and momentary investigation of the objectives for the customers. 2. In-profundity investigation of the inside and outside elements affecting the organizations development. 3. Exploring the socioeconomics best appropriate for venturing into the new market. 4. Examination of patterns through trials for outlining powerful and proficient strategies. 5. Ways to raise capital for smooth working of the associations business. 6. Working parallel to the market through proper SWOT and PESTLE examinations.

Have Any Query? Ask Our Expert @ Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

About us:

Market Research Blogs is a leading Global Research and Consulting firm servicing over 5000+ customers. Market Research Blogs provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Get More Market Research Report Click @ Market Research Blogs

See original here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Share, Growth, Trends, Outlook, Scope and Forecast to 2027 - The Haitian-Caribbean...

Market Study Report, LLC adds latest research report on Food Biotechnology Industry Market, which delivers a comprehensive study on current industry trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

This Food Biotechnology Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Food Biotechnology Industry Market at:https://www.marketstudyreport.com/request-a-sample/2727907?utm_source=cheshire.media&utm_medium=Ram

The report is also inclusive of some of the major development trends that characterize the Food Biotechnology Industry market. A comprehensive document in itself, the Food Biotechnology Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Food Biotechnology Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

, as per the report.

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Food Biotechnology Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2727907?utm_source=cheshire.media&utm_medium=Ram

Other pivotal aspects encompassed in the Food Biotechnology Industry market study:

.

.

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-food-biotechnology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. Global Sales Forecasting Software Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-sales-forecasting-software-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Application Performance Monitoring (APM) Suites Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-application-performance-monitoring-apm-suites-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Read More Reports On: https://www.marketwatch.com/press-release/copper-chlorophyll-market-segmented-by-product-top-manufacturers-geography-trends-forecasts-to-2025-2020-12-03

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the article here:
Food Biotechnology Industry Market Growth Projection from 2020 to 2026 - Cheshire Media

Text size

The tiny Vir Biotechnology was vaulted from obscurity this year, when it said it was developing treatments for Covid-19. Its stock (ticker: VIR) shot from $12 to a March peak of $75, before settling back to the mid-30swhere GlaxoSmithKline (GSK) bought a $250 million stake.

Vir started clinical trials in August for its antibody treatment against Covid-19. But the train has left the station, says Baird analyst Madhu Kumar, and Vir may have missed its Covid business opportunity. Antibodies from Eli Lilly (LLY) and Regeneron Pharmaceutical (REGN) have already gotten emergency use authorizations from regulators and booked orders. Demand for any Covid-19 treatment will start to shrink with the imminent authorization of vaccines from Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA).

In a Thursday note, Kumar reiterated his Underperform rating for Vir stock, whose shares he thinks should fall to $24 from their recent level near $32.

The Baird analyst went to a sell rating after Virs initial jump in February, and has maintained steady criticism since, in nearly 40 notes. Vir could find success with another treatment it is testing against hepatitis B, says Kumar, but future sales of such a product would only be worth $14 in current value. Ascribing $3.50 in value for Virs other pipeline programs, and counting its $6.50 a share in cash, brings Kumar to his $24 fair value.

Antibodies from Regeneron were among the treatments given to President Donald Trump in October, when he got Covid.

Newsletter Sign-up

Every weekday evening we highlight the consequential market news of the day and explain what's likely to matter tomorrow.

Virs securities filings say that its Covid-19 antibody trial could produce interim results in January 2021, and a final readout later in that years first quarter. The Baird analyst doesnt expect an authorization and product launch until the springby which point vaccines should be getting into wide supply.

Meanwhile, the bridging opportunity for anti-Covid antibodies is being snapped up by Lilly and Regeneron. The U.S. government arranged to buy 950,000 doses of Lillys treatment, including a deal for 650,000 doses announced Wednesday that will bring $850 million to Lilly.

Write to Bill Alpert at william.alpert@barrons.com

View original post here:
Vaccines and Approved Antibodies Could Dim Vir Biotechnologys Covid Opportunity - Barron's

Maharashtra

DistrictCases

Mumbai45,478

Thane13,660

Pune9,920

Mumbai Suburban5,363

Aurangabad1,974

Nashik1,575

Raigad1,462

Palghar1,421

Solapur1,291

Jalgaon1,039

Akola757

Nagpur692

Kolhapur646

Satara629

Ratnagiri350

Amravati291

Dhule228

Hingoli208

Jalna201

Ahmednagar190

Nanded176

Yavatmal150

Sangli145

Latur139

Osmanabad125

Sindhudurg114

Buldhana88

Parbhani78

gondia69

Beed54

Nandurbar42

Gadchiroli42

Bhandara41

Chandrapur32

Washim13

Wardha11

18,64,348 4,981

74,315 145

17,42,131 5,051

47,902 75

DistrictCases

Udupi1,176

Kalaburagi669

Yadgir538

Bengaluru Urban529

Raichur369

Mandya346

Belagavi337

Bidar219

Hassan205

Davangere204

Vijayapura201

Dakshina Kannada179

Chikkaballapura149

Mysuru107

Bagalkote103

Uttara Kannada95

Shivamogga67

Dharwad61

Ballari60

Gadag45

Bengaluru Rural40

Tumakuru36

Kolar29

Haveri24

Chikkamagaluru19

Chitradurga14

Koppal5

Kodagu4

Ramanagara3

Chamarajanagara0

8,96,563 1,279

23,075 1,959

8,61,588 3,218

11,900 20

DistrictCases

Kurnool795

Krishna557

Guntur511

Anantapur428

East Godavari356

Chittoor319

Sri Potti Sriramulu Nell*296

Y.S.R.205

West Godavari199

Srikakulam183

Prakasam104

Visakhapatnam103

Vizianagaram23

8,73,457 618

5,259 170

8,61,153 785

7,045 3

DistrictCases

Chennai23,324

Chengalpattu1,314

Thiruvallur774

Villupuram509

View original post here:
Department Of Biotechnology's Expert Committee Tracking Developments Related To COVID-19 Vaccine: Official | News - Swachh India NDTV

Analysts who follow PDS Biotechnology Corp (PDSB) on average expect it to increase 209.68% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns PDSB an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.

InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

PDS Biotechnology Corp (PDSB) stock is trading at $2.17 as of 1:08 PM on Wednesday, Dec 9, a loss of -$0.26, or -10.7% from the previous closing price of $2.43. The stock has traded between $2.15 and $2.40 so far today. Volume today is 585,089 compared to average volume of 614,574.

Click Here to get the full report on PDS Biotechnology Corp (PDSB) Stock.

Continued here:
Analyst Rating: Will PDS Biotechnology Corp (PDSB) Stock Outperform the Market? - InvestorsObserver

A rating of 80 puts Crispr Therapeutics AG (CRSP) near the top of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 80 means it scores higher than 80% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 36 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock is higher by 4.47% while the S&P 500 has fallen -0.3% as of 1:19 PM on Monday, Dec 7. CRSP is higher by $6.60 from the previous closing price of $147.54 on volume of 2,324,656 shares. Over the past year the S&P 500 has gained 17.61% while CRSP is higher by 128.52%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

See the rest here:
Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver

Sutro Biopharma Inc (STRO) is near the top in its industry group according to InvestorsObserver. STRO gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Sutro Biopharma Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 35 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sutro Biopharma Inc (STRO) stock is trading at $16.67 as of 12:19 PM on Thursday, Dec 3, a gain of $0.32, or 1.96% from the previous closing price of $16.35. The stock has traded between $16.23 and $17.59 so far today. Volume today is 309,465 compared to average volume of 322,449.

Click Here to get the full Stock Score Report on Sutro Biopharma Inc (STRO) Stock.

View post:
Is Sutro Biopharma Inc (STRO) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 80 puts Cellectar Biosciences Inc (CLRB) near the top of the Biotechnology industry according to InvestorsObserver. Cellectar Biosciences Inc's score of 80 means it scores higher than 80% of stocks in the industry. Cellectar Biosciences Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cellectar Biosciences Inc (CLRB) stock is trading at $2.29 as of 2:18 PM on Thursday, Dec 3, an increase of $0.34, or 17.18% from the previous closing price of $1.95. The stock has traded between $1.95 and $2.40 so far today. Volume today is high. So far 8,826,004 shares have traded compared to average volume of 928,593 shares.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Read the original:
Is Cellectar Biosciences Inc (CLRB) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

IT has been nearly two decades since the Philippine government approved the sale and cultivation of genetically modified (GM) corn seeds in local farms. The government issued a permit to commercialize Monsanto Philippiness bacillus thuringiensis (Bt) corn variety dubbed YieldGard on December 5, 2002. With this, the Philippines earned the distinction of being the first in Asia to commercialize Bt corn, a variety that enables corn farmers to save on production cost because they will no longer have to extensively use pesticides to kill the corn borera grain pest, particularly of corn.

Bt corn has been largely instrumental in increasing farmers production in the ensuing years following the issuance of the permit to Monsanto. The increment in output allowed the Philippines to become self-sufficient in corn (See, Yellow corn yield achieved 103 percent self-sufficiency last yearPiol, in the BusinessMirror, March 28, 2018). With the help of the biotech product, farmers were able to earn $642 million from 2003 to 2015, according to the International Service for the Acquisition of Agri-biotech Applications.

Its advantages and its potential to boost incomes have encouraged more farmers to plant the variety in recent years. The United States Department of Agricultures Foreign Agricultural Service in Manila noted that areas planted with Bt corn in the Philippines expanded by 26 percent to 834,617 hectares this year (See, Gain report: GE corn areas in PHL continue to expand, in the BusinessMirror, November 30, 2020). The availability of more yellow corna raw material used in manufacturing animal feedshas also supported the growing livestock and poultry industry.

These developments illustrate the benefits of biotechnology as well as its potential to enable the Philippines to develop other products that will allow farmers to diversify to other crops as well as cope with the ill effects of climate change. Currently, Bt corn is the only biotech product that is being planted in the Philippines. The GM varieties of other crops, like eggplant, are in various stages of development.

It is also worth noting that the Bt corn variety that was approved for commercialization in 2002 was made in the United States. The Philippines has yet to develop its own GM crop, and we urge Philippine researchers and scientists to make biotech products that are tailor fit to local conditions. Government must support these efforts by putting more money in the research initiatives of our local scientists or introduce policies, such as incentives, that will encourage the private sector to partner with them.

The recent successive typhoons that struck the Philippines should serve as a stark reminder of the increasing difficulties being faced by Filipino farmers and the pressing need for government to look for more sustainable means of ensuring food security. We welcome the Department of Agricultures (DA) pronouncement that it will optimize the use of biotechnology and other science-based solutions to increase farm output from limited farmlands and fishing grounds.

We urge Congress to support the DAs initiatives by passing the proposed Modern Biotechnology Act and by increasing the budget for agricultural research and development. Fully supported, our own scientists can harness the power of modern biotechnology.

Originally posted here:
Reaping the promise of biotechnology - Business Mirror

Biotechnology has experienced extraordinary growth in recent times and came to popular attention as companies raced to find vaccines and cures for COVID-19. While investing in this area has obvious appeal from a social and moral perspective, it can also be a highly lucrative space as a growth investment in a portfolio.

Biotechnology specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering.

Biotechnology is predicted to be valued at more than US$833.34bn by 2027, compared to US$447.92 billion at the end of 2019, and will continue to grow, driven by the growing global population and the need for affordable, effective treatments and vaccines.Biotechnology will also be a beneficiary of population aging, particularly in Western countries. The reason for this is that an increase in the volume of older citizens is likely to have an accompanying and proportional increase in the volume of age-related diseases such as cardiovascular disease, dementia or arthritis, all requiring treatment.

Gilead is one example of a company with prospects in this space. Gilead is already well-known for its highly effective HIV treatments but is also targeting US and European approvals to market a drug called Filgotinib to treat rheumatoid arthritis.

In a demonstration of the growth in this industry, this year alone, 30-35 biotechnology companies are anticipated to go public, raising approximately US$3.5 billion.

The healthcare sector as a whole is likely to see greater investment as a result of the COVID-19 pandemic. For example, national health spending growth in the US is expected to average 5.4% annually through 2028, reaching US$6 trillion a year. Biotechnology will also be a beneficiary of this increased investment.

Investment and value from biotechnology is expected to grow in the coming years. While the trend already existed due to continuous tech improvements and the needs of a growing population, the COVID-19 pandemic has created a new spotlight on this area which may accelerate its growth.

Australian investors are likely to already be exposed to this growth segment in the concentrated domestic market. However, they may be missing exposure to the US, which dominates the global market for biotechnology.

Biotechnology could be considered part of a sector allocation to healthcare, or investors might view it as a thematic investment. You can find more information about thematic investing and using it in your portfolio in our latest whitepaper.

There are a range of ways to access the biotechnology industry.Investors could consider direct shares in biotechnology companies or alternatively consider managed funds. Direct shares can be a high-risk approach due to the high failure rates of drug testing and long periods of development (i.e., long periods where there may be no or a limited return on investment). Theres also the element of chance has the investor picked the winner? It could take years to know.

Managed investments, be it actively managed funds or passive options like ETFs, can assist in managing risk by spreading it across a larger number of companies. Investors could choose to invest by taking a sector approach and investing in a fund focusing on broader healthcare, or look at industry-specific options focusing on biotechnology. ETFS S&P Biotech ETF (ASX Code: CURE) is one such example that offers broad exposure to US biotechnology.

Read more:
The vaccines of tomorrow: how to invest in biotechnology - Rask Media

The 62 rating InvestorsObserver gives to Agenus Inc (AGEN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AGENs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Agenus Inc (AGEN) stock is down -1.52% while the S&P 500 is higher by 0.15% as of 12:22 PM on Thursday, Dec 3. AGEN is down -$0.06 from the previous closing price of $3.63 on volume of 1,217,123 shares. Over the past year the S&P 500 has risen 18.04% while AGEN is down -9.14%. AGEN lost -$1.09 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Agenus Inc (AGEN) Stock.

Read the original here:
Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field? - InvestorsObserver

Nanoparticles In Biotechnology And Pharmaceuticals Market includes Overview, classification, industry value, price, cost and gross profit. It also covers types, enterprises and applications. To start with, analytical view to complete information of Nanoparticles In Biotechnology And Pharmaceuticals market. It offers market view by regions with countries, development in Nanoparticles In Biotechnology And Pharmaceuticals industry, opportunity with challenges, sales strategies, growth strategies and revenue analysis to include price.

The global Nanoparticles in Biotechnology and Pharmaceuticals market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nanoparticles in Biotechnology and Pharmaceuticals market based on company, product type, end user and key regions.

Get Free Sample PDF for Professional Insights:https://www.researchmoz.us/enquiry.php?type=S&repid=2404724

Nanoparticles In Biotechnology And Pharmaceuticals Market report helps to analyses competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Nanoparticles In Biotechnology And Pharmaceuticals Market Sales 2020 Industry Trend and Forecast 2026.

Market Segment by Type, covers

FullerenesLiquid CrystalsLiposomesNanoshellsQuantum dots

Nanoparticles In Biotechnology And Pharmaceuticals Market Segment by Applications, can be divided intoBiotechnologyPharmaceutical

Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia, Spain and Benelux) Asia Pacific (China, Japan, India, Southeast Asia and Australia) Latin America (Brazil, Argentina and Colombia) Middle East and Africa

Enquiry for Discount or to Get Customized Report:https://www.researchmoz.us/enquiry.php?type=D&repid=2404724

Table of Contents: Nanoparticles In Biotechnology And Pharmaceuticals Market

Get Assistance on this report at:https://www.researchmoz.us/enquiry.php?type=E&repid=2404724

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on : https://nextgenmarketresearch.blogspot.com/

Continued here:
Nanoparticles In Biotechnology And Pharmaceuticals Market Detail Analysis Focusing On Application, Types and Regional Outlook - Cheshire Media

Global Nanoparticles in Biotechnology and Pharmaceuticals Market

The Global Intelligence Insights added a new report Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

Market Overview:

Nanoparticles in Biotechnology and Pharmaceuticals Market to grow from USD 761.85 billion in 2016 and reach USD 918.74 billion by 2020, growing at a CAGR of 4.8% during the forecast period.

The global Nanoparticles in Biotechnology and Pharmaceuticals Market report offers a complete overview of the Nanoparticles in Biotechnology and Pharmaceuticals Market globally. It presents real data and statistics on the inclinations and improvements in global Nanoparticles in Biotechnology and Pharmaceuticals Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Nanoparticles in Biotechnology and Pharmaceuticals Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Nanoparticles in Biotechnology and Pharmaceuticals market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.globalintelligenceandinsights.com/request-sample-1004135

Top Key Players: Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, and Shire

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Nanoparticles in Biotechnology and Pharmaceuticals market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Market Dynamics:

The report analyzes the factors impacting the growth and the current market trends influencing the global Nanoparticles in Biotechnology and Pharmaceuticals market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Nanoparticles in Biotechnology and Pharmaceuticals market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Nanoparticles in Biotechnology and Pharmaceuticals market is also covered in the report.

Drivers & Constraints:

The report provides extensive information about the factors driving the global Nanoparticles in Biotechnology and Pharmaceuticals market. Factors influencing the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Nanoparticles in Biotechnology and Pharmaceuticals market.

Regional Segment Analysis:

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Nanoparticles in Biotechnology and Pharmaceuticals Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the key market trends impacting the growth of the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the challenges to market growth?

Who are the key vendors in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the market opportunities and threats faced by the vendors in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Nanoparticles in Biotechnology and Pharmaceuticals Market;

3.) The North American Nanoparticles in Biotechnology and Pharmaceuticals Market;

4.) The European Nanoparticles in Biotechnology and Pharmaceuticals Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Reasons for Buying this Report:

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecasts 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendixes

Get Up to 20% Discount on this Premium Report @ https://www.globalintelligenceandinsights.com/request-sample-1004135

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Global Intelligence and Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SMEs, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.

We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.

Contact Us:

Global Intelligence Insights

Bruno Abraham

US: +1-571-577-4575

202 Church Street SE,

Suite 301, Leesburg,

VA 20175

[emailprotected]

More here:
Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with...

Crispr Therapeutics AG (CRSP) is around the top of the Biotechnology industry according to InvestorsObserver. CRSP received an overall rating of 56, which means that it scores higher than 56 percent of all stocks. Crispr Therapeutics AG also achieved a score of 69 in the Biotechnology industry, putting it above 69 percent of Biotechnology stocks. Biotechnology is ranked 35 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Crispr Therapeutics AG (CRSP) stock is trading at $141.80 as of 3:01 PM on Thursday, Dec 3, a rise of $10.26, or 7.8% from the previous closing price of $131.54. The stock has traded between $130.35 and $147.82 so far today. Volume today is more active than usual. So far 1,323,678 shares have traded compared to average volume of 1,022,719 shares.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Read the original:
Is Crispr Therapeutics AG (CRSP) The Right Choice in Biotechnology? - InvestorsObserver